QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.55 (+1.12%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-1.80%)
GE   101.53 (-0.85%)
DIS   87.96 (+0.16%)
AMC   4.50 (-2.81%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.55 (+1.12%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-1.80%)
GE   101.53 (-0.85%)
DIS   87.96 (+0.16%)
AMC   4.50 (-2.81%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.55 (+1.12%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-1.80%)
GE   101.53 (-0.85%)
DIS   87.96 (+0.16%)
AMC   4.50 (-2.81%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.55 (+1.12%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-1.80%)
GE   101.53 (-0.85%)
DIS   87.96 (+0.16%)
AMC   4.50 (-2.81%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
NASDAQ:GENE

Genetic Technologies (GENE) Stock Forecast, Price & News

$0.96
-0.01 (-1.26%)
(As of 05:16 PM ET)
Compare
Today's Range
$0.95
$0.98
50-Day Range
$0.93
$1.19
52-Week Range
$0.83
$2.40
Volume
23,849 shs
Average Volume
1.41 million shs
Market Capitalization
$18.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

GENE stock logo

About Genetic Technologies (NASDAQ:GENE) Stock

Genetic Technologies Ltd. is a molecular diagnostics company, which engages in the provision of molecular risk assessment tests for cancer. It operates through EasyDNA and GeneType/Corporate segments. The EasyDNA segment focuses on EasyDNA branded test sales and expenses. The GeneType/Corporate segment includes tha GeneType branded test sales and expenses, including corporate charges. The company was founded on January 5, 1987 and is headquartered in Fitzroy, Australia.

Receive GENE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genetic Technologies and its competitors with MarketBeat's FREE daily newsletter.

GENE Stock News Headlines

Small A.I. Firm Wins $2 Billion in Contracts for Breakthrough "Living Software"
Denver firm proves its possible to use AI to save the lives of soldiers in combat. England, Germany, Japan and Australia have all signed contracts within the past 18 months. Get the name of the stock here >>>
Small A.I. Firm Wins $2 Billion in Contracts for Breakthrough "Living Software"
Denver firm proves its possible to use AI to save the lives of soldiers in combat. England, Germany, Japan and Australia have all signed contracts within the past 18 months. Get the name of the stock here >>>
Decoding genetic technologies
See More Headlines
Receive GENE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genetic Technologies and its competitors with MarketBeat's FREE daily newsletter.

GENE Company Calendar

Today
5/31/2023
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GENE
Employees
18
Year Founded
1989

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$4.86 million
Book Value
$0.77 per share

Miscellaneous

Free Float
17,993,000
Market Cap
$18.42 million
Optionable
Optionable
Beta
1.58

Social Links


Key Executives

  • Simon Morriss
    Chief Executive Officer
  • Tony di Pietro
    Chief Financial Officer & Secretary
  • Richard Allman
    Chief Scientific Officer
  • Erika Spaeth
    Director-Clinical Affairs & Medical Education
  • Carl Stubbings
    Chief Commercial Officer













GENE Stock - Frequently Asked Questions

How have GENE shares performed in 2023?

Genetic Technologies' stock was trading at $0.93 at the start of the year. Since then, GENE shares have increased by 2.9% and is now trading at $0.9572.
View the best growth stocks for 2023 here
.

What other stocks do shareholders of Genetic Technologies own?
What is Genetic Technologies' stock symbol?

Genetic Technologies trades on the NASDAQ under the ticker symbol "GENE."

Who are Genetic Technologies' major shareholders?

Genetic Technologies' stock is owned by many different retail and institutional investors. Top institutional shareholders include OLD Mission Capital LLC (0.11%).

How do I buy shares of Genetic Technologies?

Shares of GENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Genetic Technologies' stock price today?

One share of GENE stock can currently be purchased for approximately $0.96.

How much money does Genetic Technologies make?

Genetic Technologies (NASDAQ:GENE) has a market capitalization of $18.42 million and generates $4.86 million in revenue each year.

How can I contact Genetic Technologies?

Genetic Technologies' mailing address is 60-66 HANOVER STREET, FITZROY C3, 3065. The official website for the company is www.gtgcorporate.com. The biotechnology company can be reached via phone at (138) 412-7000, via email at ir@gtgcorporate.com, or via fax at 011-61-3-8412-7040.

This page (NASDAQ:GENE) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -